SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Novartis AG NVSEF OTC

Other OTC • Healthcare • Drug Manufacturers - General • CH • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Novartis AG (NVSEF) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $156.48. It has a SharesGrow Score of 73/100, indicating a above average investment profile with 5 out of 7 criteria passed.

Financials: revenue is $57.1B, +3.8%/yr average growth. Net income is $14.6B, growing at +38.9%/yr. Net profit margin is 25.6% (strong). Gross margin is 75% (+4.9 pp trend).

Balance sheet: total debt is $37.0B against $46.1B equity (Debt-to-Equity (D/E) ratio 0.8, moderate). Current ratio is 1.12 (adequate). Debt-to-assets is 32%. Total assets: $115.5B.

Analyst outlook: 5 / 20 analysts rate NVSEF as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 94/100 (Pass), Future 20/100 (Fail), Income 85/100 (Pass).

NVSEF SharesGrow Score Overview

73/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 75/100

Valuation — P/E, PEG, Forward PEG

GROWTH 73/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 94/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 85/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NVSEF

NVSEF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

NVSEF: +3.8%/yr revenue is, +38.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

NVSEF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet NVSEF: Debt-to-Equity (D/E) ratio 0.8 (moderate), Current ratio is 1.12 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

NVSEF: Gross margin is 75% (+4.9 pp trend), $299B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 94/100. ≥ 70 = Pass.

View details →

Analyst outlook: 5 / 20 analysts rate NVSEF as buy (25%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

NVSEF: Net profit margin is 25.6%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range97.3-171.29

Volume671

Avg Volume (30D)112.76K

Market Cap$298.59B

Beta (1Y)0.52

Dividend Yield$3.0878

Share Statistics

EPS (TTM)7.56

Shares Outstanding$1.94B

IPO Date2010-04-26

Employees75,883

CEOVasant Narasimhan

Financial Highlights & Ratios

Revenue (TTM)$57.13B

Gross Profit$42.86B

EBITDA$23.96B

Net Income$14.65B

Operating Income$17.8B

Total Cash$11.58B

Total Debt$37.01B

Net Debt$25.58B

Total Assets$115.49B

Price / Earnings (P/E)20.7

Price / Sales (P/S)5.23

Analyst Forecast

Rating ConsensusHold

Analysts Covering20

Buy 25% Hold 70% Sell 5%

Company Info

CountryCH

ExchangeOther OTC

CurrencyUSD

ISINCH0012005267

Price Chart

NVSEF

Novartis AG ↗ · Other OTC

Healthcare • Drug Manufacturers - General

97.30 52WK RANGE 171.29

People Also View

Roche Holding AG

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

AstraZeneca PLC

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message